Christophe Degois

Prior to joining Oncolytics, Christophe Degois was Vice President, Business Development at Dantari, a series A biotech developing novel antibody-drug conjugates for cancer. Christophe Degois started his career in the pharmaceutical industry at Eli Lilly and Co., both in Paris and in Indianapolis. He was Business Director at Schering Plough (now Merck) in Paris, where he was responsible for the launch of Remicade for rheumatoid arthritis.

He brings more than twenty years of experience in business development acquired at Genentech, PDL, Xoma, Geron, and Aimmune Therapeutics. He has closed multiple deals valued at over $3 billion, such as co-development, out-licensing, research collaborations, in-licensing, and global distribution agreements.

Christophe Degois holds an MBA with a Marketing Major from Ecole Supérieure de Commerce-SKEMA, Nice, France.